^
BIOMARKER:
HER-2 A775_G776insYVMA
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Eur J Cancer - 3 weeks
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
Eur J Cancer - 3 weeks
|
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
dacomitinib Sensitive: C3 – Early Trials
|
dacomitinib Sensitive: C3 – Early Trials
|
HER-2 A775_G776insYVMA
|
LUAD
|
HER-2 A775_G776insYVMA
|
LUAD
|
tarloxotinib bromide Sensitive: C4 – Case Studies
|
tarloxotinib bromide Sensitive: C4 – Case Studies
|
HER-2 A775_G776insYVMA
|
LUAD
|
HER-2 A775_G776insYVMA
|
LUAD
|
ado-trastuzumab emtansine Sensitive: C4 – Case Studies
|
ado-trastuzumab emtansine Sensitive: C4 – Case Studies
|
HER-2 A775_G776insYVMA
|
LUAD
|
HER-2 A775_G776insYVMA
|
LUAD
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
HER-2 A775_G776insYVMA
|
LUAD
|
HER-2 A775_G776insYVMA
|
LUAD
|
pyrotinib Sensitive: D – Preclinical
|
pyrotinib Sensitive: D – Preclinical
|
HER-2 A775_G776insYVMA
|
NSCLC
|
HER-2 A775_G776insYVMA
|
NSCLC
|
mobocertinib Sensitive: D – Preclinical
|
mobocertinib Sensitive: D – Preclinical
|
